PHI Board member Jan Richardsson recently divested 5 328 shares in the company.
“The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.
After the sale, Richardsson owns 38 634 shares in PHI, privately and via companies.
PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.